• Contact Us
TriSalus Life Sciences
  • Our Story
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Boards
  • Our Passion
  • Our Approach
    • Multi-Pronged Approach
    • Immunomodulation
      • Toll-Like Receptor 9 Agonist
    • Drug Delivery
    • Our Products
  • Our Therapeutic Pipeline
    • Pipeline Overview
    • Product Candidates
      • SD-101
    • Clinical Trials for Healthcare Professionals
    • Scientific Publications & Presentations
  • Patients & Caregivers
    • Patients
    • Our Team Approach
    • Clinical Trials for Patients
    • Patient Resources
  • News & Events
    • News
    • Events
Select Page
Trisalus life sciences’ pressure-enabled drug delivery (PEDD) significantly increased therapeutic effect of anti-CEA CAR-T in pancreatic cancer patients with liver metastases

Trisalus life sciences’ pressure-enabled drug delivery (PEDD) significantly increased therapeutic effect of anti-CEA CAR-T in pancreatic cancer patients with liver metastases

by Peter R | Nov 7, 2018 | News, News-2018

News & Events News Trisalus life sciences’ pressure-enabled drug delivery (PEDD) significantly increased therapeutic effect of anti-CEA CAR-T in pancreatic cancer patients with liver metastases CAMBRIDGE, MA—November 7, 2018—A phase 1b clinical trial shows that...
Trisalus life sciences’ pressure-enabled drug delivery (PEDD) significantly increased therapeutic effect of anti-CEA CAR-T in pancreatic cancer patients with liver metastases

Surefire Medical to Change Name to TriSalus Life Sciences

by Peter R | Sep 12, 2018 | News, News-2018

News & Events News Surefire Medical to Change Name to TriSalus Life Sciences CAMBRIDGE, MA—September 12, 2018—Surefire Medical, Inc.(Surefire) announced today the company is changing its name to TriSalus Life Sciences to better reflect the company’s contribution to...

Recent Posts

  • TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors
  • TriSalus Life Sciences to Present at the Society of Interventional Radiology’s 2022 Annual Scientific Meeting
  • TriSalus Life Sciences to Present at the Society of Interventional Radiology’s 2022 Annual Scientific Meeting
  • TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via Pressure-Enabled Drug Delivery in Adults with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
  • PERIO-01: Enabling tumor microenvironment reprogramming by a TLR9 agonist using Pressure-Enabled Drug Delivery™ (PEDD™) to address intrahepatic immunosuppression and drug delivery barriers

Recent Comments

    Our Story Our Passion Our Approach Our Therapeutic Pipeline Patients & Caregivers News Events

    TriSalus Life Sciences
    6272 W. 91st Avenue
    Westminster, CO 80031

       

    © 2021 TriSalus™    All Rights Reserved   Privacy Policy   Compliance    Terms of Use

    You are now leaving the TriSalus Life Sciences corporate website.

    We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus' standards.

    Third Party Sites
    TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of TriSalus or this website.

    Thank you for visiting our site.